Engineering Nanoplatforms for Theranostics of Atherosclerotic Plaques
Source abstract
Abstract
Abstract Atherosclerotic plaque formation is considered the primary pathological mechanism underlying atherosclerotic cardiovascular diseases, leading to severe cardiovascular events such as stroke, acute coronary syndromes, and even sudden cardiac death. Early detection and timely intervention of plaques are challenging due to the lack of typical symptoms in the initial stages. Therefore, precise early detection and intervention play a crucial role in risk stratification of atherosclerotic plaques and achieving favorable post‐interventional outcomes. The continuously advancing nanoplatforms have demonstrated numerous advantages including high signal‐to‐noise ratio, enhanced bioavailability, and specific targeting capabilities for imaging agents and therapeutic drugs, enabling effective visualization and management of atherosclerotic plaques. Motivated by these superior properties, various noninvasive imaging modalities for early recognition of plaques in the preliminary stage of atherosclerosis are comprehensively summarized. Additionally, several therapeutic strategies are proposed to enhance the efficacy of treating atherosclerotic plaques. Finally, existing challenges and promising prospects for accelerating clinical translation of nanoplatform‐based molecular imaging and therapy for atherosclerotic plaques are discussed. In conclusion, this review provides an insightful perspective on the diagnosis and therapy of atherosclerotic plaques.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Advanced Biosensing Techniques and Applications · Protease and Inhibitor Mechanisms · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Institute for Translational Medicine The Affiliated Hospital of Qingdao University College of Medicine, Qingdao University Qingdao 266021 China
Department of Cardiology The Affiliated Hospital of Qingdao University Qingdao 266003 China
Funding
Natural Science Foundation of Shandong Province · Natural Science Foundation of Qingdao Municipality
References (100+)
Show source-provided references
1. 10.1080/10641963.2020.183302510.1080/10641963.2020.1833025 ↗
2. 10.1111/pin.1320210.1111/pin.13202 ↗
3. 10.18632/aging.20494710.18632/aging.204947 ↗
4. 10.7150/ntno.6273010.7150/ntno.62730 ↗
5. 10.7150/thno.2628410.7150/thno.26284 ↗
6. 10.1002/advs.20210085010.1002/advs.202100850 ↗
7. 10.1038/s41572-019-0106-z10.1038/s41572-019-0106-z ↗
8. 10.1038/s41569-018-0119-410.1038/s41569-018-0119-4 ↗
9. 10.1021/acsami.1c1928810.1021/acsami.1c19288 ↗
10. 10.3390/ijms24171343410.3390/ijms241713434 ↗
11. 10.1063/5.015526710.1063/5.0155267 ↗
12. 10.1038/s41569-021-00629-x10.1038/s41569-021-00629-x ↗
13. 10.1002/adma.20211066010.1002/adma.202110660 ↗
14. 10.7150/ntno.6273010.7150/ntno.62730 ↗
15. 10.3389/fcvm.2022.82663010.3389/fcvm.2022.826630 ↗
16. 10.3389/fcvm.2023.115544410.3389/fcvm.2023.1155444 ↗
17. 10.3389/fphar.2023.116165710.3389/fphar.2023.1161657 ↗
18. 10.3390/ijms2403202310.3390/ijms24032023 ↗
19. 10.1161/01.CIR.0000028591.44554.F910.1161/01.CIR.0000028591.44554.F9 ↗
20. Su C. · Aging Dis. · 2023 · 14 · 1214
21. 10.1016/S1474-4422(19)30035-310.1016/S1474-4422(19)30035-3 ↗
22. 10.1007/s00018-023-04762-310.1007/s00018-023-04762-3 ↗
23. 10.1161/CIRCULATIONAHA.121.05890110.1161/CIRCULATIONAHA.121.058901 ↗
24. 10.1186/s12951-023-02040-910.1186/s12951-023-02040-9 ↗
25. 10.3389/fcvm.2023.108354710.3389/fcvm.2023.1083547 ↗
26. 10.1007/s13679-023-00506-310.1007/s13679-023-00506-3 ↗
27. 10.1186/s12944-023-01817-z10.1186/s12944-023-01817-z ↗
28. 10.1161/CIR.000000000000095010.1161/CIR.0000000000000950 ↗
29. 10.3389/fcvm.2023.95124210.3389/fcvm.2023.951242 ↗
30. 10.3389/fphar.2022.100031610.3389/fphar.2022.1000316 ↗
31. 10.3390/pharmaceutics1501022710.3390/pharmaceutics15010227 ↗
32. 10.1039/D3RA01822A10.1039/D3RA01822A ↗
33. 10.1038/nrcardio.2018.310.1038/nrcardio.2018.3 ↗
34. 10.1016/j.phrs.2019.10441310.1016/j.phrs.2019.104413 ↗
35. 10.1161/CIRCRESAHA.118.31317110.1161/CIRCRESAHA.118.313171 ↗
36. 10.1161/01.CIR.89.5.246210.1161/01.CIR.89.5.2462 ↗
37. 10.1161/01.CIR.92.5.135510.1161/01.CIR.92.5.1355 ↗
38. 10.21037/qims-19-81810.21037/qims-19-818 ↗
39. 10.3390/molecules2612361010.3390/molecules26123610 ↗
40. 10.1016/j.jfda.2017.09.00210.1016/j.jfda.2017.09.002 ↗
41. 10.1208/s12249-023-02564-110.1208/s12249-023-02564-1 ↗
42. 10.3390/ijms2403254510.3390/ijms24032545 ↗
43. 10.1039/D2TB02287G10.1039/D2TB02287G ↗
44. 10.1007/s13239-019-00411-810.1007/s13239-019-00411-8 ↗
45. 10.1038/s41467-018-03705-y10.1038/s41467-018-03705-y ↗
46. 10.1021/acs.accounts.9b0011610.1021/acs.accounts.9b00116 ↗
47. 10.1002/EXP.2023009010.1002/EXP.20230090 ↗
48. 10.1002/adma.20210534810.1002/adma.202105348 ↗
49. 10.1016/j.biomaterials.2020.12029710.1016/j.biomaterials.2020.120297 ↗
50. 10.1002/smll.20170279310.1002/smll.201702793 ↗
51. 10.1016/j.nantod.2021.10133510.1016/j.nantod.2021.101335 ↗
52. 10.1186/s12951-023-02004-z10.1186/s12951-023-02004-z ↗
53. 10.1021/acsami.3c0212810.1021/acsami.3c02128 ↗
54. 10.1021/acsami.1c0360010.1021/acsami.1c03600 ↗
55. 10.1002/adfm.20210489210.1002/adfm.202104892 ↗
56. 10.1039/D0TB00789G10.1039/D0TB00789G ↗
57. 10.1021/acsami.1c1194710.1021/acsami.1c11947 ↗
58. 10.1007/s12272-022-01418-x10.1007/s12272-022-01418-x ↗
59. 10.1039/D2NR02026B10.1039/D2NR02026B ↗
60. 10.1016/j.nantod.2022.10155410.1016/j.nantod.2022.101554 ↗
61. 10.1016/j.biomaterials.2016.02.00910.1016/j.biomaterials.2016.02.009 ↗
62. 10.1016/j.jconrel.2023.03.00810.1016/j.jconrel.2023.03.008 ↗
63. 10.1148/radiol.202120396810.1148/radiol.2021203968 ↗
64. 10.1039/D0SC04106H10.1039/D0SC04106H ↗
65. 10.1016/j.biomaterials.2017.04.03710.1016/j.biomaterials.2017.04.037 ↗
66. 10.1039/D0NR08039J10.1039/D0NR08039J ↗
67. 10.1038/ncomms1406410.1038/ncomms14064 ↗
68. 10.1016/j.biomaterials.2019.01.04310.1016/j.biomaterials.2019.01.043 ↗
69. 10.1021/acsnano.7b0138510.1021/acsnano.7b01385 ↗
70. 10.1016/j.jcmg.2016.01.02010.1016/j.jcmg.2016.01.020 ↗
71. 10.1002/adma.20210699410.1002/adma.202106994 ↗
72. 10.1016/j.biomaterials.2022.12173410.1016/j.biomaterials.2022.121734 ↗
73. 10.1002/adma.20200749010.1002/adma.202007490 ↗
74. 10.1016/j.biomaterials.2016.03.04910.1016/j.biomaterials.2016.03.049 ↗
75. 10.2147/IJN.S38273810.2147/IJN.S382738 ↗
76. 10.1002/adma.20200003710.1002/adma.202000037 ↗
77. 10.1002/adfm.20210100510.1002/adfm.202101005 ↗
78. 10.1021/acs.nanolett.1c0135910.1021/acs.nanolett.1c01359 ↗
79. 10.1007/s11547-021-01366-410.1007/s11547-021-01366-4 ↗
80. Odle T. · Radiol. Technol. · 2020 · 91
81. 10.3389/fcvm.2021.71682210.3389/fcvm.2021.716822 ↗
82. 10.1038/s41565-022-01081-910.1038/s41565-022-01081-9 ↗
83. 10.1021/jacs.8b0581710.1021/jacs.8b05817 ↗
84. 10.1021/acsnano.0c0345710.1021/acsnano.0c03457 ↗
85. 10.1002/wnan.148010.1002/wnan.1480 ↗
86. 10.1016/j.cej.2019.12217210.1016/j.cej.2019.122172 ↗
87. 10.1021/ar300150c10.1021/ar300150c ↗
88. 10.1021/ja071471p10.1021/ja071471p ↗
89. 10.2217/imt-2018-002910.2217/imt-2018-0029 ↗
90. 10.7150/thno.7962510.7150/thno.79625 ↗
91. 10.3390/diagnostics1303049910.3390/diagnostics13030499 ↗
92. 10.3389/fcvm.2022.110944510.3389/fcvm.2022.1109445 ↗
93. 10.7150/ntno.7957510.7150/ntno.79575 ↗
94. 10.1016/j.jcmg.2015.02.00610.1016/j.jcmg.2015.02.006 ↗
95. 10.1002/adhm.20200033610.1002/adhm.202000336 ↗
96. 10.1016/j.biomaterials.2012.09.02510.1016/j.biomaterials.2012.09.025 ↗
97. 10.3390/jcdd1005020710.3390/jcdd10050207 ↗
98. Czaja‐Ziółkowska M. Z. · Postepy Kardiol. Interwencyjnej · 2022 · 18 · 201
99. 10.3390/diagnostics1304064510.3390/diagnostics13040645 ↗
100. Chen K. · IEEE J. Biomed. Health Inform. · 2023 · 27